Shares of Antibe Therapeutics Inc. (TSE:ATE – Get Free Report) were up 13.5% on Monday . The stock traded as high as C$0.35 and last traded at C$0.30. Approximately 167,042 shares were traded during trading, an increase of 23% from the average daily volume of 135,475 shares. The stock had previously closed at C$0.26.
Antibe Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.58 and a current ratio of 10.06. The firm has a market capitalization of C$15.64 million, a price-to-earnings ratio of -0.84 and a beta of 0.19. The company has a 50 day moving average price of C$0.30 and a two-hundred day moving average price of C$0.58.
Antibe Therapeutics Company Profile
Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
Featured Articles
- Five stocks we like better than Antibe Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- How Much Can You Make in Stocks in One Month?
- Pros And Cons Of Monthly Dividend Stocks
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Invest in Blue Chip Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
